Pliant Therapeutics Announces Upcoming Presentations at the 2025 American Thoracic Society International Conference
Pliant Therapeutics (Nasdaq: PLRX) has announced its participation in the 2025 American Thoracic Society (ATS) International Conference in San Francisco from May 16-21, 2025. The company will present three scientific works, including:
1. A featured oral presentation by Dr. Johanna Schaub on Bexotegrast's antifibrotic activity in ILD subtypes (May 19, 2:15-4:15 PM PT)
2. A poster presentation by Dr. Richard Ahn on plasma proteome analysis of ILD subtypes (May 21, 8:15-10:15 AM PT)
3. A poster by Dr. Mahru An on single-cell profiling of Bexotegrast's antifibrotic effects (May 21, 8:15-10:15 AM PT)
All presentations will be available for registered conference attendees and later on Pliant's website.
Pliant Therapeutics (Nasdaq: PLRX) ha annunciato la sua partecipazione alla Conferenza Internazionale della Società Americana di Tisiologia (ATS) 2025 che si terrà a San Francisco dal 16 al 21 maggio 2025. L'azienda presenterà tre lavori scientifici, tra cui:
1. Una presentazione orale di rilievo della Dr.ssa Johanna Schaub sull'attività antifibrotica di Bexotegrast nei sottotipi di ILD (19 maggio, 14:15-16:15 PT)
2. Una presentazione poster del Dr. Richard Ahn sull'analisi del proteoma plasmatico dei sottotipi di ILD (21 maggio, 8:15-10:15 PT)
3. Un poster del Dr. Mahru An sul profilo cellulare singolo degli effetti antifibrotici di Bexotegrast (21 maggio, 8:15-10:15 PT)
Tutte le presentazioni saranno disponibili per i partecipanti registrati alla conferenza e successivamente sul sito web di Pliant.
Pliant Therapeutics (Nasdaq: PLRX) ha anunciado su participación en la Conferencia Internacional de la Sociedad Americana de Neumología (ATS) 2025 en San Francisco del 16 al 21 de mayo de 2025. La empresa presentará tres trabajos científicos, incluyendo:
1. Una presentación oral destacada de la Dra. Johanna Schaub sobre la actividad antifibrótica de Bexotegrast en subtipos de ILD (19 de mayo, 14:15-16:15 PT)
2. Una presentación de póster del Dr. Richard Ahn sobre el análisis del proteoma plasmático de subtipos de ILD (21 de mayo, 8:15-10:15 PT)
3. Un póster del Dr. Mahru An sobre el perfil celular único de los efectos antifibróticos de Bexotegrast (21 de mayo, 8:15-10:15 PT)
Todas las presentaciones estarán disponibles para los asistentes registrados a la conferencia y más tarde en el sitio web de Pliant.
Pliant Therapeutics (Nasdaq: PLRX)는 2025년 5월 16일부터 21일까지 샌프란시스코에서 열리는 미국 호흡기학회(ATS) 국제 회의에 참여한다고 발표했습니다. 회사는 다음을 포함하여 세 가지 과학적 작업을 발표할 예정입니다:
1. Dr. Johanna Schaub의 Bexotegrast의 항섬유화 활성에 대한 구두 발표 (5월 19일, 오후 2:15-4:15 PT)
2. Dr. Richard Ahn의 ILD 하위 유형에 대한 혈장 단백질체 분석에 대한 포스터 발표 (5월 21일, 오전 8:15-10:15 PT)
3. Dr. Mahru An의 Bexotegrast의 항섬유화 효과에 대한 단일 세포 프로파일링 포스터 (5월 21일, 오전 8:15-10:15 PT)
모든 발표는 등록된 회의 참석자를 위해 제공되며, 이후 Pliant의 웹사이트에서도 확인할 수 있습니다.
Pliant Therapeutics (Nasdaq: PLRX) a annoncé sa participation à la Conférence Internationale de la Société Américaine de Thoracologie (ATS) 2025 qui se tiendra à San Francisco du 16 au 21 mai 2025. L'entreprise présentera trois travaux scientifiques, dont :
1. Une présentation orale de la Dr. Johanna Schaub sur l'activité antifibrotique de Bexotegrast dans les sous-types de ILD (19 mai, 14h15-16h15 PT)
2. Une présentation par affiche du Dr. Richard Ahn sur l'analyse du protéome plasmatique des sous-types de ILD (21 mai, 8h15-10h15 PT)
3. Une affiche du Dr. Mahru An sur le profilage cellulaire unique des effets antifibrotiques de Bexotegrast (21 mai, 8h15-10h15 PT)
Toutes les présentations seront disponibles pour les participants enregistrés à la conférence et plus tard sur le site web de Pliant.
Pliant Therapeutics (Nasdaq: PLRX) hat seine Teilnahme an der 2025 American Thoracic Society (ATS) International Conference in San Francisco vom 16. bis 21. Mai 2025 bekannt gegeben. Das Unternehmen wird drei wissenschaftliche Arbeiten präsentieren, darunter:
1. Einen herausragenden Vortrag von Dr. Johanna Schaub über die antifibrotische Aktivität von Bexotegrast bei ILD-Subtypen (19. Mai, 14:15-16:15 PT)
2. Eine Posterpräsentation von Dr. Richard Ahn zur Plasma-Proteomanalyse von ILD-Subtypen (21. Mai, 8:15-10:15 PT)
3. Ein Poster von Dr. Mahru An über die Einzelzellprofilierung der antifibrotischen Effekte von Bexotegrast (21. Mai, 8:15-10:15 PT)
Alle Präsentationen werden für registrierte Konferenzteilnehmer verfügbar sein und später auf der Website von Pliant zu finden sein.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., April 07, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that the Company will present three scientific posters at the upcoming 2025 American Thoracic Society (ATS) International Conference, taking place in San Francisco, California from May 16-21, 2025.
The following abstracts are posted on ATS 2025’s online itinerary planner for registered users.
Pliant was selected for a featured oral presentation as part of the ATS 2025 Mini Symposiums program.
Title: Characterizing the Antifibrotic Activity of Bexotegrast on Distinct Fibroblast Populations in PCLS From Multiple ILD Subtypes
Presenter: Johanna Schaub, Ph.D., Director of Translational Sciences at Pliant Therapeutics
Oral Presentation: 9696
Session B98: Cellular interactions and signaling networks in pulmonary fibrosis (mini symposium)
Date: Monday, May 19, 2025
Presentation Time: 2:15 p.m. – 4:15 p.m. Pacific Time
Title: Plasma Proteome Analysis Reveals Shared and Unique Biomarkers of ILD Subtypes
Presenter: Richard Ahn, Ph.D., Senior Scientist II at Pliant Therapeutics
Poster: 12006
Session D29: From bench to bedside: unraveling pulmonary fibrosis through cellular communication and molecular pathways
Date: Wednesday, May 21, 2025
Presentation Time: 8:15 a.m. – 10:15 a.m. Pacific Time
Title: Single-Cell Profiling Demonstrates the Antifibrotic Effects of Bexotegrast on Pathologic Lung Cell Populations in the Presence and Absence of Background Therapy
Presenter: Mahru An, Ph.D., Principal Scientist at Pliant Therapeutics
Poster: 12106
Session D29: From bench to bedside: unraveling pulmonary fibrosis through cellular communication and molecular pathways
Date: Wednesday, May 21, 2025
Presentation Time: 8:15 a.m. – 10:15 a.m. Pacific Time
Posters will be available to view during the ATS Conference, Sunday, May 18 - Wednesday, May 21 during the above times for registered users and on the Presentations page of the company website at www.PliantRx.com.
About Pliant Therapeutics, Inc.
Pliant Therapeutics is a late-stage biopharmaceutical company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases. Pliant's lead product candidate, bexotegrast (PLN-74809), is an oral, small molecule, dual selective inhibitor of αvß6 and αvß1 integrins that is in development in the lead indication for the treatment of idiopathic pulmonary fibrosis, or IPF. Bexotegrast has received Fast Track Designation and Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) and Orphan Drug Designation from the European Medicines Agency in IPF. Pliant is conducting a Phase 1 study for PLN-101095, a small molecule, dual-selective inhibitor of αvß8 and αvß1 integrins, that is being developed for the treatment of solid tumors. In addition, Pliant has received regulatory clearance for the conduct of a Phase 1 study of PLN-101325, a monoclonal antibody agonist of integrin α7β1 targeting muscular dystrophies.
For additional information, please visit: www.PliantRx.com. Follow us on social media X, LinkedIn, and Facebook.
Investor and Media Contact:
Christopher Keenan
Vice President, Investor Relations and Corporate Communications
Pliant Therapeutics, Inc.
ir@pliantrx.com
FAQ
What will Pliant Therapeutics present at ATS 2025 regarding Bexotegrast?
When are PLRX's presentation times at the 2025 ATS Conference?
How many scientific presentations will PLRX deliver at ATS 2025?
Where can investors view PLRX's ATS 2025 conference presentations?
What research topics will PLRX present at the 2025 ATS Conference?
